ICPT News and Press, Intercept Pharmaceuticals Inc. From 09/20/23

2023-09-20 11:55:57 ET More on Health Care Sector: Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Health Care Select Sector SPDR ETF declares quarterly distribution of $0.5395 BofA clients were net buyers of U.S. equities for a fifth consecutiv...

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...

2023-08-24 07:41:04 ET Summary Akero Therapeutics is a biopharmaceutical company focused on developing therapies for nonalcoholic steatohepatitis (NASH). NASH is a severe form of non-alcoholic fatty liver disease that can lead to liver failure and other serious health complication...

2023-08-14 16:31:43 ET UBS has initiated coverage of Cymabay Therapeutics ( NASDAQ: CBAY ) with a buy rating, stating it sees a Phase 3 study for the company’s drug seladelpar in the treatment of primary biliary cholangitis, or PBC, yielding positive data. UBS said it exp...

2023-08-14 13:19:20 ET Despite recent setbacks, drugmakers are still forging ahead in their quest to develop effective treatments for non-alcoholic steatohepatitis, or NASH, a growing public health concern that could represent a roughly $108B global market opportunity by 2030. According...

2023-08-03 18:45:41 ET Summary Intercept Pharmaceuticals' Q2 earnings reveal 17% growth in revenue and focus on Ocaliva for treating PBC, discontinuing NASH development. Despite strong revenue growth and promising Ocaliva expansion, concerns include substantial debt and lingering ...

2023-08-02 11:28:05 ET Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and CEO Andrew Saik - Chief Financial Of...

2023-08-02 07:06:46 ET Intercept Pharma press release ( NASDAQ: ICPT ): Q2 GAAP EPS of -$0.14 beats by $0.38 . Revenue of $83.72M (+16.7% Y/Y) beats by $4.15M. As of June 30, 2023, Intercept had cash, cash equivalents, restricted cash, and investment debt secur...

Ocaliva® (obeticholic acid or OCA) net sales of $83.7 million, representing 17% growth over the prior year quarter Company updates full-year 2023 Ocaliva net sales guidance to $320 million to $340 million; reiterates non-GAAP adjusted operating expense guidance of $350 million to $...